Deals Shaping The Medical Industry, February 2013
Executive Summary
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
You may also be interested in...
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
The latest drug development news and highlights from our FDA Performance Tracker.
Swiss Finally Beat EMA On New Drug Approval Times
More rolling reviews, a reduction in review rounds, and a rise in applications through two international regulatory collaboration initiatives were among the factors behind a reduction in new drug authorization times in Switzerland last year. However, “submission gaps” versus other regulators remain a problem.
Sanofi Abandons Oral SERD Breast Cancer Drug As Pipeline Woes Mount
The Paris-headquartered company has thrown in the towel on its oral SERD, leaving Roche, Eli Lilly and AstraZeneca to pursue Menarini in the field.